FDA Relabels Warfarin, Recommends Genetic Testing

Posted September 18, 2007 by Dr. T.R. Morris

With the FDA’s recent relabeling of warfarin, the real clinical challenge in determining appropriate dosage is understanding which genetic warfarin dosing panel to order. There are different tests in application. It is important to order a test that takes into account all of the ethnic variants in the sequence. This is a critical point for providers to understand when ordering these dosing tests.